Your browser doesn't support javascript.
loading
Characterizing mortality in patients with AQP4-Ab+ neuromyelitis optica spectrum disorder.
Francis, Anna; Gibbons, Emily; Yu, Jeffrey; Johnston, Karissa; Rochon, Hannah; Powell, Lauren; Leite, Maria Isabel; Huda, Saif; Kielhorn, Adrian; Palace, Jacqueline.
Afiliación
  • Francis A; Oxford University Hospital, Oxford, UK.
  • Gibbons E; The Walton Centre NHS Foundation Trust, Liverpool, UK.
  • Yu J; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Johnston K; Broadstreet Health Economics & Outcomes Research, Vancouver, British Columbia, Canada.
  • Rochon H; Broadstreet Health Economics & Outcomes Research, Vancouver, British Columbia, Canada.
  • Powell L; Broadstreet Health Economics & Outcomes Research, Vancouver, British Columbia, Canada.
  • Leite MI; Department of Clinical Neurosciences, Oxford University Hospitals, Oxford, UK.
  • Huda S; Guy's and St Thomas's NHS Foundation Trust, Liverpool, UK.
  • Kielhorn A; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Palace J; Oxford University Hospital, Oxford, UK.
Ann Clin Transl Neurol ; 11(7): 1942-1947, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38884180
ABSTRACT
Neuromyelitis optica spectrum disorder is an autoimmune disease, causing severe disability due to relapses, but recent mortality data are limited. Among 396 patients seropositive for anti-aquaporin-4 antibody from 2014 to 2020 in the United Kingdom, 39 deaths occurred 19 (48.7%) were unrelated to disease; 14 (35.9%) were severe disability- or relapse-related; and 4 (10.3%) were attributed to malignancy/infection. Mean annual mortality was 1.92% versus 0.63% in the matched population. The standardized mortality ratio was 3.04 (95% confidence interval 1.67-5.30) with 1.29% excess mortality per year in patients. Median Expanded Disability Status Scale before death was 7.0. Results highlight the importance of preventing relapses that drive disability.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Autoanticuerpos / Neuromielitis Óptica / Acuaporina 4 País/Región como asunto: Europa Idioma: En Revista: Ann Clin Transl Neurol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Autoanticuerpos / Neuromielitis Óptica / Acuaporina 4 País/Región como asunto: Europa Idioma: En Revista: Ann Clin Transl Neurol Año: 2024 Tipo del documento: Article